June 14, 2026 — RNews

#immunomodulation — Sunday, June 14, 2026 (1 items)

hot top new

← prev day next day →

0

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial. (linkinghub.elsevier.com)

Dimopoulos MA … Richardson PG The Lancet 2026-06-14

#amr #clinical trial #immunomodulation #multiple myeloma